Superiority of iRhythm's Zio Long-Term Continuous Monitoring Service Eyed

 IRTC announced that the results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events (CAMELOT) study have been published in the American Heart Journal (AHJ).

The peer-reviewed manuscript, titled “Comparative Effectiveness and Healthcare Utilization for Ambulatory Cardiac Monitoring (ACM) Strategies in Medicare Beneficiaries,” reveals that the Zio long-term continuous monitoring service (LTCM), which features up to 14 continuous days of monitoring, was independently associated with the highest yield of clinical arrhythmia encounter diagnosis and lowest likelihood of retest. The retrospective study of almost 300,000 patients makes CAMELOT the largest published real-world comparative effectiveness analysis of ambulatory cardiac monitoring.

“Our findings reveal significant variation in selection of monitoring devices, which can be influenced by patient characteristics and other factors. However, long-term continuous monitoring — and iRhythm’s Zio LTCM in particular — was independently associated with a higher probability of an arrhythmia diagnosis being documented and a lower probability of repeat testing," said Matthew Reynolds, MD, MSc, a cardiac electrophysiologist at Lahey Hospital & Medical Center and the study's lead author. “LTCM also minimized subsequent health care spending, compared to traditional Holter monitors or non-continuous event monitors. We believe these findings may be useful for clinicians in choosing the best type of monitor for different clinical scenarios.”

https://www.globenewswire.com/news-release/2024/01/05/2804624/0/en/Largest-Ever-Real-World-Evidence-Study-of-Ambulatory-Cardiac-Monitoring-Demonstrates-Clinical-Superiority-of-iRhythm-s-Zio-Long-Term-Continuous-Monitoring-Service.html